HMGB1 is involved in chronic rejection of cardiac allograft via promoting inflammatory-like mDCs

American Journal of Transplantation

Volumn 14, Issue 8, 2014, Pages 1765-1777

  Zou, H ^a,b,c   Yang, Y ^a,b,c   Gao, M ^a,b,c   Zhang, B ^a,b,c   Ming, B ^a,b,c   Sun, Y ^a,b,c   Chen, H ^a,b,c   Tang, X ^a,b,c   Chen, Z ^a,b,c   Xiong, P ^a,b,c   Xu, Y ^a,b,c   Fang, M ^a,b,c   Tan, Z ^a,b,c   Gong, F ^a,b,c   Zheng, F ^a,b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Cardiac allograft; chronic rejection; DC; HMGB1; IFN ; IL 17A

Indexed keywords

GAMMA INTERFERON; HIGH MOBILITY GROUP B1 MONOCLONAL ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 2; HMGB1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELL INFILTRATION; CELL MATURATION; CELL SUBPOPULATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FIBROSIS; HEART TRANSPLANTATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CYTOLOGY; FLOW CYTOMETRY; GENETICS; GRAFT REJECTION; HEART FAILURE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; PHYSIOLOGY;

ANIMALS; DENDRITIC CELLS; FEMALE; FIBROSIS; FLOW CYTOMETRY; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HMGB1 PROTEIN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; PHENOTYPE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84904624900     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12781     Document Type: Article

References (61)

1. Lee MS, Finch W, Weisz G, Kirtane AJ., Cardiac allograft vasculopathy. Rev Cardiovasc Med 2011; 12: 143-152.
2. Weiss MJ, Madsen JC, Rosengard BR, Allan JS., Mechanisms of chronic rejection in cardiothoracic transplantation. Front Biosci 2008; 13: 2980-2988.
3. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133-3144.
4. Hagemeijer MC, van Oosterhout MF, van Wichen DF, et al. T cells in cardiac allograft vasculopathy are skewed to memory Th-1 cells in the presence of a distinct Th-2 population. Am J Transplant 2008; 8: 1040-1050.
5. Faust SM, Lu G, Marini BL, et al. Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J Immunol 2009; 183: 7297-7306.
6. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
7. Banchereau J, Steinman RM., Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
8. Lechler RI, Sykes M, Thomson AW, Turka LA., Organ transplantation-How much of the promise has been realized ? Nat Med 2005; 11: 605-613.
9. Hornick P., Direct indirect allorecognition. Methods Mol Biol 2006; 333: 145-156.
10. Huang YL, Wang YZ, Chen JB, et al. Prevention of acute and chronic allograft rejection by combinations of tolerogenic dendritic cells. Scand J Immunol 2011; 73: 91-101.
11. Suzuki J, Isobe M, Morishita R, Nagai R., Characteristics of chronic rejection in heart transplantation: Important elements of pathogenesis and future treatments. Circ J 2010; 74: 233-239.
12. Savasta M, Lentini S., Immunology insights into cardiac allograft rejection. Rev Cardiovasc Med 2011; 12: e68-e76.
13. Matzinger P., Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
14. Matzinger P., The danger model: A renewed sense of self. Science 2002; 296: 301-305.
15. Ulloa L, Messmer D., High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev 2006; 17: 189-201.
16. Huang Y, Yin H, Han J, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7: 799-808.
17. Duan L, Wang CY, Chen J, et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab Invest 2011; 91: 43-53.
18. Moser B, Szabolcs MJ, Ankersmit HJ, et al. Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant 2007; 7: 293-302.
19. Xia Q, Duan L, Shi L, Zheng F, Gong F, Fang M., High-mobility group box 1 accelerates early acute allograft rejection via enhancing IL-17(+) gammadelta T-cell response. Transpl Int 2014; 27: 399-407.
20. Mengle-Gaw L, Conner S, McDevitt HO, Fathman CG., Gene conversion between murine class II major histocompatibility complex loci. Functional and molecular evidence from the bm 12 mutant. J Exp Med 1984; 160: 1184-1194.
21. Corry RJ, Winn HJ, Russell PS., Heart transplantation in congenic strains of mice. Transplant Proc 1973; 5: 733-735.
22. Zhu H, Li J, Wang S, Liu K, Wang L, Huang L., Gammadelta T cell receptor deficiency attenuated cardiac allograft vasculopathy and promoted regulatory T cell expansion. Scand J Immunol 2013; 78: 44-49.
23. Wang W, Sun L, Deng Y, Tang J., Synergistic effects of antibodies against high-mobility group box 1 and tumor necrosis factor-alpha antibodies on d -(+)-galactosamine hydrochloride/lipopolysaccharide-induced acute liver failure. FEBS J 2013; 280: 1409-1419.
24. Zhou H, Wang Y, Wang W, et al. Generation of monoclonal antibodies against highly conserved antigens. PLoS ONE 2009; 4: e6087.
25. Furukawa Y, Libby P, Stinn JL, Becker G, Mitchell RN., Cold ischemia induces isograft arteriopathy, but does not augment allograft arteriopathy in non-immunosuppressed hosts. Am J Pathol 2002; 160: 1077-1087.
26. + TCR transgenic mouse. Am J Transplant 2003; 3: 381-389.
27. Tanaka M, Fedoseyeva EV, Robbins RC., Graft coronary artery disease in murine cardiac allografts: Proposal to meet the need for standardized assessment. J Heart Lung Transplant 2005; 24: 316-322.
28. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
29. Kwun J, Oh BC, Gibby AC, et al. Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. Am J Transplant 2012; 12: 2641-2651.
30. Terasaki PI., The review by Kwun and Knechtle-"Can it B?"-asks whether B cells are responsible for chronic rejection of transplants. Transplantation 2009; 88: 978-979.
31. Terasaki PI, Cai J., Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377-383.
32. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
33. Sunderkotter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-4417.
34. Rivollier A, He J, Kole A, Valatas V, Kelsall BL., Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med 2012; 209: 139-155.
35. Castiello L, Sabatino M, Jin P, et al. Monocyte-derived DC maturation strategies and related pathways: A transcriptional view. Cancer Immunol Immunother 2011; 60: 457-466.
36. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K., Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
37. Segura E, Amigorena S., Inflammatory dendritic cells in mice and humans. Trends Immunol 2013; 34: 440-445.
38. Shiozawa S, Tsumiyama K., Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009; 8: 1539-1543.
39. Yanai H, Ban T, Taniguchi T., High-mobility group box family of proteins: Ligand and sensor for innate immunity. Trends Immunol 2012; 33: 633-640.
40. Andersson U, Tracey KJ., HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
41. Tang D, Kang R, Zeh HJ III, Lotze MT., High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14: 1315-1335.
42. Yan SF, Ramasamy R, Schmidt AM., The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009; 11: e9.
43. Lu CY, Winterberg PD, Chen J, Hartono JR., Acute kidney injury: A conspiracy of Toll-like receptor 4 on endothelia, leukocytes, and tubules. Pediatr Nephrol 2012; 27: 1847-1854.
44. Wang Q, Wang F, Li X, et al. Electroacupuncture pretreatment attenuates cerebral ischemic injury through alpha7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats. J Neuroinflamm 2012; 9: 24.
45. Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: Role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24: 2320-2325.
46. Park S, Yoon SJ, Tae HJ, Shim CY., RAGE and cardiovascular disease. Front Biosci (Landmark Ed) 2011; 16: 486-497.
47. Inoue K, Kawahara K, Biswas KK, et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007; 16: 136-143.
48. Kanazawa H, Tochino Y, Asai K, Ichimaru Y, Watanabe T, Hirata K., Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD. Eur J Clin Invest 2012; 42: 419-426.
49. Hou C, Zhao H, Liu L, et al. High mobility group protein B1 (HMGB1) in asthma: Comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med 2011; 17: 807-815.
50. Han J, Zhong J, Wei W, et al. Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 2008; 57: 2118-2127.
51. Bianchi ME., HMGB1 loves company. J Leukoc Biol 2009; 86: 573-576.
52. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ., HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
53. Lotze MT, Tracey KJ., High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
54. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307-313.
55. Telusma G, Datta S, Mihajlov I, et al. Dendritic cell activating peptides induce distinct cytokine profiles. Int Immunol 2006; 18: 1563-1573.
56. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205: 869-882.
57. Ma Y, Adjemian S, Mattarollo SR, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38: 729-741.
58. Wood KJ, Bushell A, Hester J., Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417-430.
59. Schierbeck H, Lundback P, Palmblad K, et al. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 2011; 17: 1039-1044.
60. Robinson AP, Caldis MW, Harp CT, Goings GE, Miller SD., High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis. J Autoimmun 2013; 43: 32-43.
61. Uzawa A, Mori M, Taniguchi J, Masuda S, Muto M, Kuwabara S., Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol 2013; 172: 37-43.